keyword
MENU ▼
Read by QxMD icon Read
search

Infiximab

keyword
https://www.readbyqxmd.com/read/26670274/low-dose-infliximab-for-prevention-of-postoperative-recurrence-of-crohn-s-disease-long-term-follow-up-and-impact-of-infliximab-trough-levels-and-antibodies-to-infliximab
#1
Dario Sorrentino, Marco Marino, Themistocles Dassopoulos, Dimitra Zarifi, Tiziana Del Bianco
OBJECTIVE: In patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg). However, in theory low-dose infliximab treated patients could develop subtherapeutic trough levels, infiximab antibodies, and might loose response to therapy. To verify this hypothesis infliximab pharmacokinetics and clinical/endoscopic response were checked in a group of patients treated in the long term with low infliximab doses...
2015: PloS One
https://www.readbyqxmd.com/read/25897110/-eosinophilic-fasciitis
#2
REVIEW
Karolina Niklas, Arkadiusz Niklas, Mariusz Puszczewicz
Eosinophilic fasciitis is a rare connective tissue disease with unclear etiology and pathogenesis. It is classified as a scleroderma-like syndrome. The disease is characterized by fibrosis of the skin and subcutaneous tissues with significant thickening of fascia. Visceral involvement is rare. Characteristic feature in laboratory tests is peripheral blood eosinophilia. Differential diagnosis should be performed, including ruling out systemic sclerosis, nephrogenic systemic fibrosis, eosinophilia-myalgia syndrome, scleromyxedema, hypereosinophilic syndrome or Churg-Strauss syndrome...
2015: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/25513628/long-term-study-of-infliximab-for-psoriasis-in-daily-practice-drug-survival-depends-on-combined-treatment-obesity-and-infusion-reactions
#3
J Spertino, A Lopez-Ferrer, E Vilarrasa, L Puig
BACKGROUND: Infiximab has been shown to be highly effective in phase III clinical trials, but limited information is available regarding drug survival and maintenance of efficacy beyond 1 year in real-life clinical setting. OBJECTIVES: To analyse the efficacy and safety of infliximab in a large number of patients with a long follow-up and to identify clinical factors associated with long-term drug survival. METHODS: A retrospective review of patients with moderate-to-severe psoriasis treated with infliximab from March 2004 to August 2012 at a tertiary dermatology centre was carried out...
November 2014: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/25493314/long-term-study-of-infliximab-for-psoriasis-in-daily-practice-drug-survival-depends-on-combined-treatment-obesity-and-infusion-reactions
#4
J Spertino, A Lopez-Ferrer, E Vilarrasa, L Puig
BACKGROUND: Infiximab has been shown to be highly effective in phase III clinical trials, but limited information is available regarding drug survival and maintenance of efficacy beyond 1 year in real-life clinical setting. OBJECTIVES: To analyse the efficacy and safety of infliximab in a large number of patients with a long follow-up and to identify clinical factors associated with long-term drug survival. METHODS: A retrospective review of patients with moderate-to-severe psoriasis treated with infliximab from March 2004 to August 2012 at a tertiary dermatology centre was carried out...
November 2014: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/25083091/need-for-infliximab-dose-intensification-in-crohn-s-disease-and-ulcerative-colitis
#5
COMPARATIVE STUDY
Carlos Taxonera, David Olivares, Juan L Mendoza, Manuel Díaz-Rubio, Enrique Rey
AIM: To compare the need for infliximab dose intensification in two cohorts of patients with Crohn's disease (CD) or ulcerative colitis (UC). METHODS: Single centre, uncontrolled, observational study. Consecutive patients with CD and UC who responded to infliximab induction doses were included. Data collected in a prospectively maintained database were retrospectively analysed. Differences in the rates of dose intensification per patient-month and the intensification-free survival time were compared...
July 21, 2014: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/24984403/safety-of-infliximab-in-children-with-ibd-the-experience-of-an-academic-center-in-wv
#6
Michael Northcutt, Awni Al-Subu, Brooke Bella, Yoram Elitsur
BACKGROUND: The immune-modulating drug, infliximab, is approved for Inflammatory Bowel Disease (IBD) treatment in children. Chronic therapy with infliximab is associated with the development of early and delayed infusion reactions. We reviewed our experience with infliximab treatment and its side effects in a cohort of children diagnosed with IBD who were treated in our clinic. METHODS: A retrospective analysis of all IBD children treated with infliximab in our center from 2006-2011 was performed...
May 2014: West Virginia Medical Journal
https://www.readbyqxmd.com/read/23698951/cement-embolization-to-right-atrium-and-pulmonary-artery-after-percutaneous-vertebroplasty
#7
Samir Diab, Mohammad Diab
SESSION TYPE: DVT/PE/Pulmonary Hypertension Posters IIPRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PMPURPOSE: This particular complication of vertebroplasty calls for better awareness and care against such complication.METHODS: A 28-year male with 4-year history of ulcerative colitis was maintained on prednisolone, mesalazine and infiximab. He underwent cement vertebroplasty for severe lumbar spine osteoporosis, 24 hours after which he developed right pleuritic pain and dyspnea. Chest X-ray,Echocardiogram, Chest CT-Angiogram and Lab tests were performed...
October 1, 2012: Chest
https://www.readbyqxmd.com/read/23235598/methotrexate-for-induction-of-remission-in-refractory-crohn-s-disease
#8
REVIEW
John W D McDonald, David J Tsoulis, John K Macdonald, Brian G Feagan
BACKGROUND: Although corticosteroids are effective for induction of remission of Crohn's disease, many patients relapse when steroids are withdrawn or become steroid dependent. Furthermore, corticosteroids exhibit significant adverse effects. The success of methotrexate as a treatment for rheumatoid arthritis led to its evaluation in patients with refractory Crohn's disease. Methotrexate has been studied for induction of remission of refractory Crohn's disease and has become the principal alternative to azathioprine or 6-mercaptopurine therapy...
2012: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/22197901/cytokines-and-behcet-s-disease
#9
Z Y Zhou, S L Chen, N Shen, Y Lu
Behcet's Disease (BD) is a systemic vasculitis of unknown etiology. Increasing studies find that a sophisticated interlacing cytokine network is closely implicated in the onset, evolution and even organ damages of the disease. Cytokines involved can be categorized as Th1 type, Th2 type, Th17 type, chemokines and other proinflammatory cytokines, etc. The vicious cycle of cytokine network plays a substantial role in the disease pathogenesis and even in organ lesions, and might be disorganized by blocking one of the key links of the cytokines, which in turn may provide essential clues to outlook the target therapy regimen of cytokine agents in BD...
August 2012: Autoimmunity Reviews
https://www.readbyqxmd.com/read/20969553/tnf-inhibitors-new-and-old-agents-for-rheumatoid-arthritis
#10
REVIEW
Ismail Simsek
The development of tumor necrosis factor (TNF) inhibitor therapy has revolutionized the treatment of rheumatoid arthritis (RA). Unfortunately, no one single agent is fully effective in every patient; different patients respond to different therapies in different ways, even to those agents with the same mechanism of action. In this regard, newer TNF inhibitor agents, such as golimumab and certolizumab pegol, are a welcome addition to the treatment armamentarium of RA. This article addresses some of the recent advances in TNF inhibitor therapy for RA, including therapy involving these two newer agents and recent recommendations about well established TNF inhibitors (infiximab, etanercept, adalimumab) that may affect various aspects of RA treatment strategies...
2010: Bulletin of the NYU Hospital for Joint Diseases
https://www.readbyqxmd.com/read/20969545/t-cell-agents-in-the-treatment-of-rheumatoid-arthritis
#11
REVIEW
Gary E Solomon
T cells play a prominent role in the pathogenesis of rheumatoid arthritis. Abatacept is the first FDA approved agent for rheumatoid arthritis that blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and the CD80/86 ligand on the antigen presenting cell. Inhibition of T cell activation has pleotropic effects that lowers the downstream production of multiple cytokines. In clinical trials, abatacept is effective in treating the signs and symptoms of rheumatoid arthritis as well as in inhibiting structural damage...
2010: Bulletin of the NYU Hospital for Joint Diseases
https://www.readbyqxmd.com/read/20187505/-effects-and-safety-of-infliximab-administration-in-refractory-uveoretinitis-with-beh%C3%A3-et-s-disease
#12
Hiroyuki Tanaka, Sunao Sugita, Yukiko Yamada, Tatsushi Kawaguchi, Yoichi Iwanaga, Koju Kamoi, Mako Yokota, Hiroshi Takase, Manabu Mochizuki
PURPOSE: To evaluate the efficacy and safety of infliximab administration in refractory uveoretinitis in Behçet's disease (BD). METHODS: The subjects were 22 consecutive BD patients with refractory uveoretinitis treated with infliximab. Three patients dropped out from the therapy. The other 19 patients received the therapy for 6 months or longer. The efficacy was evaluated by the ocular attacks and best corrected visual acuity at remission in the 19 patients and the safety was evaluated in all 22 patients...
February 2010: Nippon Ganka Gakkai Zasshi
https://www.readbyqxmd.com/read/19852747/can-rapid3-an-index-without-formal-joint-counts-or-laboratory-tests-serve-to-guide-rheumatologists-in-tight-control-of-rheumatoid-arthritis-in-usual-clinical-care
#13
REVIEW
Theodore Pincus
Tight control of rheumatoid arthritis (RA) may be guided by RAPID3 (routine assessment of patient index data), an index without formal joint counts or laboratory tests, which can be scored on a multidimensional health assessment questionnaire (MDHAQ) in 5 seconds, compared to 42 seconds to score a standard HAQ, 90 seconds to perform a 28-joint count, 114 seconds to score a disease activity score 28 (DAS28), and 106 seconds to score a clinical disease activity index (CDAI). RAPID3 scores are correlated significantly with DAS28 and CDAI (rho > 0...
2009: Bulletin of the NYU Hospital for Joint Diseases
https://www.readbyqxmd.com/read/19459571/-biologic-therapy-of-rheumatoid-arthritis
#14
REVIEW
Nemanja Damjanov, Jelena Vojinović
Rheumatoid arthritis (RA) and juvenile idiopathic/rheumatoid arthritis (JIA) are chronic, inflammatory, systemic, autoimmune diseases characterized by chronic arthritis leading to progressive joint erosions. The individual functional and social impact of rheumatoid arthritis is of great importance. Disability and joint damage occur rapidly and early in the course of the disease. The remarkably improved outcomes have been achieved initiating biologic therapy with close monitoring of disease progression. Biologic agents are drugs, usually proteins, which can influence chronic immune dysregulation resulting in chronic arthritis...
March 2009: Srpski Arhiv za Celokupno Lekarstvo
https://www.readbyqxmd.com/read/15476155/long-term-treatment-of-rectovaginal-fistulas-in-crohn-s-disease-response-to-infliximab-in-the-accent-ii-study
#15
RANDOMIZED CONTROLLED TRIAL
Bruce E Sands, Marion A Blank, Kam Patel, Sander J van Deventer
BACKGROUND & AIMS: The ACCENT II study (A Crohn's Disease Clinical Trial Evaluating Infiximab in a New Long-term Treatment Regimen in Patients With Fistulizing Crohn's Disease) evaluated the efficacy and safety of infliximab maintenance treatment in patients with fistulizing Crohn's disease. This post hoc analysis was conducted to determine the efficacy and safety of infliximab therapy in women with rectovaginal fistulas. METHODS: All patients received 5 mg/kg infliximab intravenously at weeks 0, 2, and 6...
October 2004: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/12496713/-etanercept-infliximab-switch-in-rheumatoid-arthritis-14-out-of-131-patients-treated-with-anti-tnfalpha
#16
COMPARATIVE STUDY
O Brocq, Y Plubel, V Breuil, C Grisot, P Flory, A Mousnier, L Euller-Ziegler
OBJECTIVE: Patients with severe rheumatoid arthritis and resistant to at least three DMARDS can benefit from anti-TNFalpha (tumor necrosis factor) therapy. In some patients, because of inefficacy or adverse events, treatment with one of the two available TNFalpha drugs (etanercept and infliximab) must be stopped. In this study, we explored the results in efficacy and tolerance of switching from one anti-TNFalpha to the other. PATIENTS: Between August 1999 and January 2002, we administered one of the two anti TNFalpha drugs to 131 patients: 67 patients received infiximab and 64 etanercept...
November 23, 2002: La Presse Médicale
https://www.readbyqxmd.com/read/11846051/efficacy-of-methylprednisolone-pulse-therapy-versus-infliximab-in-the-treatment-of-severe-flares-of-chronic-polyarthritis
#17
COMPARATIVE STUDY
H C Nossent, G Bakland, H K Aslaksen, G Olsen, B Y Nordvåg
BACKGROUND: To compare short term efficacy of pulse intravenous (iv) Methylprednisolone (MP) versus Infiximab in flares of polyarthritis. PATIENTS-METHODS: Observational study of consecutive patients admitted with flares of chronic polyarthritis. Treatment consisted of three iv doses of MP 1000mg on alternate days (MP-group, n = 10) or of Infliximab will be 3 mg/kg at baseline, two, and six weeks later (I-group, n=9). DMARD therapy was initiated/continued in all patients...
2001: Scandinavian Journal of Rheumatology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"